Feasibility and Clinical Utility of Cell-free DNA (cfDNA) in Identifying Actionable Alterations and Minimal Residual Disease for Lymphoma Patients Across Community Centers in Texas

Part of paid clinical trials in Houston, Texas.

Sponsor
M.D. Anderson Cancer Center
Study ID
NCT05676450
Status
Recruiting

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • cell-free DNA — DIAGNOSTIC_TEST
    Given by IV (vein)

Study Details

To test the feasibility of collecting cell-free DNA (cfDNA) samples from DLBCL patients before and after treatment. cfDNA is DNA traveling in your blood outside of a cell and is easily collected from blood samples drawn using the vein puncture method.

Key Dates

Start date
Feb 23, 2023
Status verified
May 2026
Primary completion
Aug 31, 2026
Completion
Aug 31, 2026

Study Design

Enrollment
517 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC

Arms

  • Other: cell-free DNA (cfDNA) samples
    cell-free DNA (cfDNA) samples from DLBCL participants before and after treatment. cfDNA is DNA traveling in your blood outside of a cell and is easily collected from blood samples drawn using the vein puncture method. Blood will be drawn 3 times (by vein)

Primary Outcome Measure

Overall Survival (OS) [ Time Frame: through study completion; an average 1 year ]

Central Contacts

Locations (2)

FacilityCityStateZIPSite coordinators
MD Anderson Cancer CenterHoustonTexas77030
Chijioke Nze, MD
832-729-1752
Chijioke Nze, MD (PRINCIPAL_INVESTIGATOR)
Cancer Therapy and Research Center at The UT Health Science Center at San AntonioSan AntonioTexas78229
Adolfo Enriques Diaz Duque, MD
210-450-1209
Adolfo Enriques Diaz Duque, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Houston, TX

Related Studies